Wellcome Trust

International AMR Action! 21 Sep Wellcome Trust-UNGA event / 12-13 Oct Call to Action (Berlin)

Dear All:  The international conversation continues apace following the recent DRIVE-AB meeting on antibiotic incentives. There are two further important meetings coming up that you may wish to know about. First, Wellcome Trust is co-hosting a side-event with the UN Foundation during the UN General Assembly on 21 Sep (yes, this week!). The side event is from 8a-10a in

Read More »

RFP: Climate-Sensitive Infectious Disease Modelling

Dear All, And now for something really different! With the recent GRAM report (20 Jan 2022 newsletter) showing that AMR is linked to more deaths that HIV or malaria (#AMRSOS! Andrew Jack and FT team have some great graphics for this … check them out!), we now have an absolutely fascinating call from Wellcome Trust for

Read More »

Calls for proposals: US CDC, UK-China, Wellcome Trust

Dear All: As we head into the Easter and Passover weekend, three new calls for proposals have emerged! Perhaps one of these is for you? The US CDC has released a Broad Agency Announcement (FY2018-OADS-BAA) seeking proposals for projects across a range of areas (diagnostics, transmission, microbiome disruption, resistance genes in the environment, and stewardship). Initial proposals

Read More »

Stewardship & Access Guide from CARB-X, Wellcome, and partners: Analysis, video chat

Dear All, Novel antibacterial agents, vaccines, and diagnostics will do little if they are not widely available and used responsibly. CDDEP’s recent report entitled “The State of the World’s Antibiotics in 2021” makes this very clear: “… more people in LMICs (low-middle-income countries) die from lack of access to antimicrobials than from resistant infection.” Hence, CARB-X has

Read More »

Wellcome Trust RFP: Landscape Report on Early antibiotic development

Dear All, The Wellcome Trust Drug-Resistant Infections team wants to understand what researchers in academia and SMEs need to enable them to be better able to make progress with their early antibiotic discovery projects. Although some programs are now in place (e.g., the accelerator support provided by CARB-X), what are the remaining barriers?  To help

Read More »
Scroll to Top